171 related articles for article (PubMed ID: 34305941)
1. Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody.
Kim N; Yu JI; Lim DH; Lee J; Kim ST; Hong JY; Kang WK; Jeong WK; Kim KM
Front Immunol; 2021; 12():701668. PubMed ID: 34305941
[TBL] [Abstract][Full Text] [Related]
2. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab.
Kim N; Yu JI; Park HC; Yoo GS; Choi C; Hong JY; Lim HY; Lee J; Choi MS; Lee JE; Kim K
Cancer Immunol Immunother; 2021 Jun; 70(6):1593-1603. PubMed ID: 33231725
[TBL] [Abstract][Full Text] [Related]
3. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
[TBL] [Abstract][Full Text] [Related]
4. Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.
Panda A; Mehnert JM; Hirshfield KM; Riedlinger G; Damare S; Saunders T; Kane M; Sokol L; Stein MN; Poplin E; Rodriguez-Rodriguez L; Silk AW; Aisner J; Chan N; Malhotra J; Frankel M; Kaufman HL; Ali S; Ross JS; White EP; Bhanot G; Ganesan S
J Natl Cancer Inst; 2018 Mar; 110(3):316-320. PubMed ID: 29155997
[TBL] [Abstract][Full Text] [Related]
5. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.
Liu X; Choi MG; Kim K; Kim KM; Kim ST; Park SH; Cristescu R; Peter S; Lee J
Pathol Res Pract; 2020 Apr; 216(4):152881. PubMed ID: 32089413
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors.
Kim YY; Lee J; Jeong WK; Kim ST; Kim JH; Hong JY; Kang WK; Kim KM; Sohn I; Choi D
Gastric Cancer; 2021 Mar; 24(2):457-466. PubMed ID: 32970267
[TBL] [Abstract][Full Text] [Related]
7. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W
Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786
[TBL] [Abstract][Full Text] [Related]
8. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype.
Cho CJ; Kang HJ; Ryu YM; Park YS; Jeong HJ; Park YM; Lim H; Lee JH; Song HJ; Jung HY; Kim SY; Myung SJ
Gastric Cancer; 2018 Nov; 21(6):925-935. PubMed ID: 29627937
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite instability and Epstein-Barr virus combined with PD-L1 could serve as a potential strategy for predicting the prognosis and efficacy of postoperative chemotherapy in gastric cancer.
Yang N; Wu Y; Jin M; Jia Z; Wang Y; Cao D; Qin L; Wang X; Zheng M; Cao X; Jiang J
PeerJ; 2021; 9():e11481. PubMed ID: 34046266
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
[TBL] [Abstract][Full Text] [Related]
11. Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability.
Kohlruss M; Grosser B; Krenauer M; Slotta-Huspenina J; Jesinghaus M; Blank S; Novotny A; Reiche M; Schmidt T; Ismani L; Hapfelmeier A; Mathias D; Meyer P; Gaida MM; Bauer L; Ott K; Weichert W; Keller G
J Pathol Clin Res; 2019 Oct; 5(4):227-239. PubMed ID: 31206244
[TBL] [Abstract][Full Text] [Related]
12. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
[TBL] [Abstract][Full Text] [Related]
13. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
Chen EX; Jonker DJ; Loree JM; Kennecke HF; Berry SR; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski SL; Wei AC; Magoski NM; Tu D; O'Callaghan CJ
JAMA Oncol; 2020 Jun; 6(6):831-838. PubMed ID: 32379280
[TBL] [Abstract][Full Text] [Related]
14. The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors.
Gullo I; Carvalho J; Martins D; Lemos D; Monteiro AR; Ferreira M; Das K; Tan P; Oliveira C; Carneiro F; Oliveira P
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018250
[TBL] [Abstract][Full Text] [Related]
15. Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection.
Chiaravalli AM; Feltri M; Bertolini V; Bagnoli E; Furlan D; Cerutti R; Novario R; Capella C
Virchows Arch; 2006 Mar; 448(3):344-53. PubMed ID: 16261379
[TBL] [Abstract][Full Text] [Related]
16. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
Derks S; Liao X; Chiaravalli AM; Xu X; Camargo MC; Solcia E; Sessa F; Fleitas T; Freeman GJ; Rodig SJ; Rabkin CS; Bass AJ
Oncotarget; 2016 May; 7(22):32925-32. PubMed ID: 27147580
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.
Ameratunga M; Chénard-Poirier M; Moreno Candilejo I; Pedregal M; Lui A; Dolling D; Aversa C; Ingles Garces A; Ang JE; Banerji U; Kaye S; Gan H; Doger B; Moreno V; de Bono J; Lopez J
Eur J Cancer; 2018 Jan; 89():56-63. PubMed ID: 29227818
[TBL] [Abstract][Full Text] [Related]
18. Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial.
Roh CK; Choi YY; Choi S; Seo WJ; Cho M; Jang E; Son T; Kim HI; Kim H; Hyung WJ; Huh YM; Noh SH; Cheong JH
Yonsei Med J; 2019 Feb; 60(2):132-139. PubMed ID: 30666834
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of CT-determined sarcopenia in patients with advanced gastric cancer.
Lee JS; Kim YS; Kim EY; Jin W
PLoS One; 2018; 13(8):e0202700. PubMed ID: 30125312
[TBL] [Abstract][Full Text] [Related]
20. Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials.
Biesma HD; Soeratram TTD; Sikorska K; Caspers IA; van Essen HF; Egthuijsen JMP; Mookhoek A; van Laarhoven HWM; van Berge Henegouwen MI; Nordsmark M; van der Peet DL; Warmerdam FARM; Geenen MM; Loosveld OJL; Portielje JEA; Los M; Heideman DAM; Meershoek-Klein Kranenbarg E; Hartgrink HH; van Sandick J; Verheij M; van de Velde CJH; Cats A; Ylstra B; van Grieken NCT
Gastric Cancer; 2022 May; 25(3):640-651. PubMed ID: 35129727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
